Veru Inc. VERU
Set alert
At close · Nov 2
After hours · Nov 2, 4:00 PM ET
- YTD
- +0.93%
- 1 year
- -26.78%
- Open
- 2.20
- Prev close
- 2.19
- Mkt cap
- 36.83M
- Vol
- 249.37K
- Avg vol
- 220.04K
- EPS
- -0.61
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.08
- High
- 2.22
- Forward P/E
- -2.23
- Beta
- -0.46
- Short ratio
- 13.35
- Inst. own
- 42.04%
- Dividend
- 0.00
- Ex-div date
- Apr 27, 2014
- 50-d avg
- 0.7422
- 200-d avg
- 0.90395
- 1y target
- 3.40
News
-
3 weeks ago benzinga.com
WestPark Capital Initiates Coverage On Veru with Buy Rating, Announces Price Target of $28
WestPark Capital analyst Ed Arce initiates coverage on Veru (NASDAQ:VERU) with a Buy rating and announces Price Target of $28.
1 month ago globenewswire.com
Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines' RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial
--New positive preclinical studies show that sabizabulin can overcome drug resistance to daraxonrasib with potent anticancer efficacy (IC50=18.2nM) in daraxonrasib resistant human pancreatic cancer…
2 months ago globenewswire.com
Veru to Participate in Fireside Chat at the 2026 Cantor Global Healthcare Conference
MIAMI, FL, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic…
2 months ago seekingalpha.com
Veru Inc. (VERU) Q3 2026 Earnings Call Transcript
Veru Inc. (VERU) Q3 2026 Earnings Call Transcript
-
2 months ago benzinga.com
Veru Q3 EPS $(0.30) Beats $(0.32) Estimate
Veru (NASDAQ:VERU) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.32) by 6.25 percent. This is a 40 percent increase over losses of $(0.50) per share…
2 months ago globenewswire.com
Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress
-- Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients –
3 months ago globenewswire.com
Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss
-- When issued U.S. patent protection until at least October 2044 -- -- Allowed patent adds to already issued enobosarm specific molecule polymorph composition of matter patents, as well as number of…
3 months ago globenewswire.com
Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th
MIAMI, FL, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic…
3 months ago globenewswire.com
Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference
MIAMI, FL, July 30, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic…
-
3 months ago benzinga.com
Veru Completes Patient Enrollment In Phase 2b PLATEAU Clinical Trial To Evaluate Effect Of Oral Enobosarm 3 Mg Versus To Treat Obesity
Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced…
3 months ago globenewswire.com
Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
-- Phase 2b PLATEAU clinical trial exceeds targeted full enrollment of 200 patients — -- Interim analysis results on track for calendar Q1 ‘27-- MIAMI, FL, July 27, 2026 (GLOBE NEWSWIRE) -- Veru Inc.…
3 months ago globenewswire.com
Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day
MIAMI, FL, July 07, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic…
5 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
-
5 months ago benzinga.com
Veru Strikes Clinical Supply Agreement With Novo Nordisk To Mull Combination Of Enobosarm With Wegovy
https://www.sec.gov/ix?doc=/Archives/edgar/data/863894/000143774926019478/veru20260601_8k.htm
-
5 months ago benzinga.com
Oppenheimer Maintains Outperform on Veru, Lowers Price Target to $24
Oppenheimer analyst Leland Gershell maintains Veru (NASDAQ:VERU) with a Outperform and lowers the price target from $25 to $24.
5 months ago seekingalpha.com
Veru Inc. (VERU) Q2 2026 Earnings Call Prepared Remarks Transcript
Veru Inc. (VERU) Q2 2026 Earnings Call Prepared Remarks Transcript
5 months ago benzinga.com
Transcript: Veru Q2 2026 Earnings Conference Call
Transcript: Veru Q2 2026 Earnings Conference Call
-
5 months ago benzinga.com
Veru Q2 EPS $(0.12) Beats $(0.28) Estimate
Veru (NASDAQ:VERU) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.28) by 57.14 percent. This is a 76 percent increase over losses of $(0.50) per share…
5 months ago globenewswire.com
Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress
--Phase 2b PLATEAU clinical study evaluating enobosarm + semaglutide is actively enrolling and on track for i nterim analysis first quarter calendar year 2027 —
6 months ago globenewswire.com
Veru to Report Fiscal 2026 Second Quarter Financial Results on May 13th
MIAMI, FL, May 06, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic…
6 months ago defenseworld.net
Veru (NASDAQ:VERU) Share Price Crosses Below 200 Day Moving Average – Here’s Why
Veru Inc. (NASDAQ: VERU - Get Free Report)'s stock price crossed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $2.64 and traded as low as…
6 months ago defenseworld.net
Veru (NASDAQ:VERU) Stock Passes Below 200 Day Moving Average – Should You Sell?
Veru Inc. (NASDAQ: VERU - Get Free Report) shares passed below its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $2.69 and traded as low as $2.39. Veru…
-
6 months ago benzinga.com
Veru Files Prospectus For Offering $200M Mixed Shelf
https://www.sec.gov/Archives/edgar/data/863894/000119312526145576/d84893ds3.htm
7 months ago defenseworld.net
Veru (NASDAQ:VERU) Shares Cross Below 200 Day Moving Average – Here’s Why
Veru Inc. (NASDAQ: VERU - Get Free Report)'s stock price passed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $2.81 and traded as low as…
-
7 months ago benzinga.com
Veru Enrolls First Patient In Phase 2b PLATEAU Clinical Trial Of Enobosarm, Oral SARM, To Preserve Muscle And Physical Function And To Augment Fat And Weight Loss When Combined With Wegovy
-- The Phase 2b study to assess enobosarm's ability to preserve lean mass, physical function, and bone as well as burn more fat to produce greater quality and quantity of weight loss in older…
7 months ago globenewswire.com
Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
-- The Phase 2b study to assess enobosarm's ability to preserve lean mass, physical function, and bone as well as burn more fat to produce greater quality and quantity of weight loss in older…
8 months ago seekingalpha.com
Veru Inc. (VERU) Q1 2026 Earnings Call Transcript
Veru Inc. (VERU) Q1 2026 Earnings Call Transcript
-
8 months ago benzinga.com
Veru Q1 EPS $(0.26) Beats $(0.47) Estimate
Veru (NASDAQ:VERU) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.47) by 44.68 percent. This is a 57.38 percent increase over losses of $(0.61) per…
-
8 months ago benzinga.com
Earnings Scheduled For February 11, 2026
Earnings Scheduled For February 11, 2026
8 months ago benzinga.com
A Look at Veru's Upcoming Earnings Report
A Look at Veru's Upcoming Earnings Report
8 months ago defenseworld.net
Flora Growth (NASDAQ:FLGC) and Veru (NASDAQ:VERU) Financial Review
Veru (NASDAQ: VERU - Get Free Report) and Flora Growth (NASDAQ: FLGC - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based…
9 months ago globenewswire.com
Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th
MIAMI, FL, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic…
10 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
10 months ago benzinga.com
Canaccord Genuity Initiates Coverage On Veru with Buy Rating, Announces Price Target of $25
Canaccord Genuity analyst Edward Nash initiates coverage on Veru (NASDAQ:VERU) with a Buy rating and announces Price Target of $25.
10 months ago seekingalpha.com
Veru Inc. (VERU) Q4 2025 Earnings Call Transcript
Veru Inc. (VERU) Q4 2025 Earnings Call Transcript
-
10 months ago benzinga.com
Earnings Scheduled For December 17, 2025
Earnings Scheduled For December 17, 2025
10 months ago benzinga.com
A Look Ahead: Veru's Earnings Forecast
A Look Ahead: Veru's Earnings Forecast
10 months ago benzinga.com
Top Wall Street Forecasters Revamp Veru Expectations Ahead Of Q4 Earnings
Top Wall Street Forecasters Revamp Veru Expectations Ahead Of Q4 Earnings
10 months ago benzinga.com
Top Stocks With Earnings This Week: Micron, FuelCell, Carnival and More
Investors are prepping for this week's earnings reports which include homebuilders, several apparel companies and a big tech company.
-
1 year ago benzinga.com
Veru to Present Enobosarm Data At ObesityWeek 2025 Highlighting Lean Mass Preservation And Fat Loss Selectivity
Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced the…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
-
1 year ago benzinga.com
Veru Announces Pricing Of $25M Public Offering Of 1.4M Shares Of Common Stock At A Price Of $3.00 Per Unit
Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, announced today the…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
1 year ago benzinga.com
Veru Reveals Proposed Public Offering; No Size Disclosed
Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, announced today…
-
1 year ago benzinga.com
Earnings Scheduled For August 12, 2025
Earnings Scheduled For August 12, 2025
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
-
1 year ago benzinga.com
Earnings Scheduled For February 13, 2025
Earnings Scheduled For February 13, 2025